PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment

J Mol Med (Berl). 2013 Dec;91(12):1383-97. doi: 10.1007/s00109-013-1076-3. Epub 2013 Aug 18.

Abstract

Both phosphatidylinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin signaling and antiapoptotic Bcl-2 family members are critical for survival of acute myeloid leukemia (AML) cells. Here, we demonstrate the antileukemic effects of simultaneous inhibition of PI3K by the selective class I PI3K inhibitor GDC-0941 and of Bcl-2 family members by the BH3 mimetic ABT-737 in the context of the bone marrow microenvironment, where hypoxia and interactions with bone marrow stromal cells promote AML cell survival and chemoresistance. The combination of GDC-0941 and ABT-737 profoundly downregulated antiapoptotic Mcl-1 expression levels, activated BAX, and induced mitochondrial apoptosis in AML cells co-cultured with bone marrow stromal cells under hypoxic conditions. Hypoxia caused degradation of Mcl-1 and rendered Mcl-1-overexpressing OCI-AML3 cells sensitive to ABT-737. Our findings suggest that pharmacologic PI3K inhibition by GDC-0941 enhances ABT-737-induced leukemia cell death even under the protective conditions afforded by the bone marrow microenvironment.

Key message: Combined blockade of PI3K and Bcl-2 pathways down-regulates anti-apoptotic Mcl-1 expression PI3K and Bcl-2 induced Mcl-1 down-regulation activates BAX PI3K and Bcl-2 blockage induces apoptosis in AML under hypoxic BM microenvironment.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects*
  • Biphenyl Compounds / pharmacology*
  • Bone Marrow / drug effects*
  • Bone Marrow / metabolism*
  • Bone Marrow / pathology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Coculture Techniques
  • Drug Synergism
  • Gene Expression Regulation, Leukemic
  • Humans
  • Hypoxia / metabolism
  • Indazoles / pharmacology*
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / metabolism*
  • Mesenchymal Stem Cells / drug effects
  • Mesenchymal Stem Cells / metabolism
  • Myeloid Cell Leukemia Sequence 1 Protein / genetics
  • Myeloid Cell Leukemia Sequence 1 Protein / metabolism
  • Nitrophenols / pharmacology*
  • Phosphoinositide-3 Kinase Inhibitors
  • Piperazines / pharmacology
  • RNA Interference
  • Sulfonamides / pharmacology*
  • Tumor Microenvironment / drug effects*
  • Tumor Microenvironment / genetics

Substances

  • 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
  • ABT-737
  • Biphenyl Compounds
  • Indazoles
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Nitrophenols
  • Phosphoinositide-3 Kinase Inhibitors
  • Piperazines
  • Sulfonamides